EGFR and neoplasm: In the present study, afatinib showed favorable ORR and PFS regardless of the tumor EGFRm status results, similar to the findings of previous trials assessing afatinib as first‐line treatment of EGFR‐mutated NSCLC based on tumor genotyping.3, 4, 5